ChAdOx1 – AstraZeneca + University of Oxford showed no clear difference in all‐cause mortalityf compared with placebo (low certainty).
BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in all‐cause mortalityg compared with placebo (low certainty).
AD26.COV2.S – Janssen Pharmaceutical Companies leads to lower all‐cause mortalityb compared with placebo (high certainty).
It is very uncertain whether gam‐COVID‐VAC – Sputnik V changes all‐cause mortalityf compared with placebo (very low certainty).
CoronaVac – Sinovac showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).
The review found no eligible studies for this question.
BBV152 – Bharat Biotech showed no clear difference in all‐cause mortalitye compared with placebo (low certainty).
NVX‐CoV2373 – Novavax showed no clear difference in all‐cause mortalityh compared with placebo (low certainty).
FINLAY‐FR‐2 – Instituto Finlay de Vacunas probably leads to lower all‐cause mortalitye compared with placebo (moderate certainty).
Extended prophylaxis showed no clear difference in all‐cause mortalityg compared with placebo (moderate certainty).
Prostaglandin showed no clear difference in all‐cause mortality ( compared with placebo or standard care (low certainty).
Aclidinium bromide showed no clear difference in mortality (all‐cause) compared with placebo (low certainty).
Long‐acting beta2‐agonists showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
It is very uncertain whether sarilumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
It is very uncertain whether clazakizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
It is very uncertain whether olokizumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
It is very uncertain whether siltuximab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
It is very uncertain whether levilimab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).
Tociliuzumab leads to lower all‐cause mortality D28 compared with standard care/placebo (high certainty).
Canakinumab showed no clear difference in all‐cause mortality D28 compared with standard care/placebo (low certainty).